Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories reports company news centered on veterinary diagnostics, software and animal-health testing. Recurring updates cover CAG Diagnostics recurring revenue, reference laboratory services, in-clinic analyzers, premium instrument placements and financial guidance tied to veterinary practice demand in the U.S. and international regions.
Company announcements also describe product innovation across pet healthcare, including IDEXX Cancer Dx testing, IDEXX inVue Dx, digital imaging systems such as Vue DR50 Plus, Web PACS software and connected workflow tools for veterinary practices. Other recurring topics include investor conference participation, governance and leadership updates, and products that support milk and water safety and livestock health.
IDEXX Laboratories reported a 19% revenue growth for Q3 2020, reaching $722 million, primarily driven by a 23% growth in Companion Animal Group (CAG) Diagnostics recurring revenue. The company achieved an Earnings per Share (EPS) of $1.69, reflecting a 36% increase. Although the CAG business performed well, revenue was constrained by lower instrument placements and a 5% decline in Water revenues. IDEXX is cautious regarding future guidance due to the ongoing COVID-19 pandemic impacts.
IDEXX Laboratories (NASDAQ: IDXX) announced that it will release its 2020 third quarter financial results on October 29, 2020, before the market opens. An analyst conference call will follow at 8:30 a.m. ET, accessible via a live webcast on the IDEXX website. The call can also be accessed by phone with specific dialing instructions provided. IDEXX, a leader in veterinary diagnostics and pet healthcare innovation, operates globally with over 9,000 employees and serves customers in more than 175 countries.
IDEXX Laboratories (NASDAQ: IDXX) reported positive trends in the U.S. Companion Animal Market as of July 31, 2020. Same-store clinical visits rose by 6%, while total practice revenue increased by 10%. These metrics reflect continued growth in companion animal healthcare, signaling strong demand for IDEXX's veterinary diagnostics and software solutions. The insights were made available on IDEXX's investor relations website.
IDEXX Laboratories (NASDAQ: IDXX) has expanded its imaging portfolio with the introduction of the ImageVue® DR30 Digital Imaging System. This system enhances image contrast and sharpness while reducing radiation doses by 25% or more. Positioned as an affordable option, it targets veterinary practices upgrading from older systems, providing significant efficiency improvements with a 70% faster workflow. The launch reflects IDEXX's commitment to innovation in veterinary diagnostics, ensuring better care for pets and safety for veterinary staff.
IDEXX Laboratories (NASDAQ: IDXX) announced the launch of the ProCyte One Hematology Analyzer on August 12, 2020. This analyzer promises breakthrough workflow simplicity and delivers reference laboratory-quality results at the point of care. Currently available for pre-sale in North America and select European markets, volume shipping is expected in the first quarter of 2021. The ProCyte One features unique pay-per-run and auto-replenishment models, enhancing financial flexibility for veterinarians while simplifying the diagnostic process.
IDEXX Laboratories (NASDAQ: IDXX) will host its 2020 virtual Investor Day on August 13, 2020, from 10:00 am to 12:00 pm ET. This event features executive presentations and a Q&A session with the senior leadership team, including Jay Mazelsky, Brian McKeon, and others. A live webcast will be available at www.idexx.com/investors, and an archived replay will be accessible shortly after the event. As a leader in veterinary diagnostics and healthcare innovation, IDEXX serves customers in over 175 countries.
IDEXX Laboratories reports a 3% revenue increase to $638 million for Q2 2020, with 4% organic growth, bolstered by a 7% rise in Companion Animal Group (CAG) Diagnostics. EPS rose 20% to $1.72, reflecting effective cost control and operational efficiency. However, new CAG instrument placements and Water business revenues faced declines due to COVID-19 impacts. Notable growth in CAG diagnostics was observed, supported by improved clinical visit trends. The company has suspended full-year guidance amid ongoing pandemic uncertainty.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) will release its second-quarter financial results for 2020 on July 31, 2020, before market opening. The company will hold an analyst conference call at 8:30 a.m. ET, accessible via a webcast on their website. A virtual Investor Day is scheduled for August 13, 2020, from 10:00 a.m. to 12:00 p.m. ET, with a replay available post-event. IDEXX, a leader in veterinary diagnostics, employs over 9,000 people and serves customers in over 175 countries.